SCOTLAND’S BOLD MOVE FROM PLASTIC WASTE
A team of Scottish researchers is blazing a trail in the pharmaceutical industry by exploring an innovative process that could transform plastic waste from industrial processes into pharmaceuticals targeted at neurological conditions.
packaging manufacturer API Foilmakers, and the Industrial Biotechnology Innovation Centre (IBioIC), this visionary project is poised to revolutionize drug manufacturing and environmental sustainability simultaneously.
S
Central to this pioneering effort is a new approach to recycling polyethylene terephthalate (PET), a commonly used plastic in food and drink packaging production. Unlike traditional recycling methods, this project marks the first time PET plastic is being considered as a viable starting material for manufacturing essential medications.
By harnessing the power of genetically modified bacteria and enzymes, the researchers aim to break down PET plastic waste into core chemical components that can be converted into pharmaceuticals for treating a range of life- limiting neurological conditions.
Playing a pivotal role in the project, Livingston- based API Foilmakers supplies the raw PET material. The firm produces rolls of plastic- backed foil, stretching to approximately 18 kilometres each month. However, the precision- driven printing process leaves no room for error, as a single flaw can render an entire roll unusable, generating significant PET waste, potentially up to 100 tonnes. This collaboration therefore not only seeks to address the plastic waste conundrum but also strives to create an effective and sustainable pathway for producing crucial neuropharmaceuticals.
While enzymatic breakdown of PET has been explored by other companies, the quality of resulting plastic often falls short, contributing to long-term landfill concerns. In contrast, this ground-breaking Scottish initiative promises a paradigm shift, tapping into PET's potential to deliver high-quality pharmaceutical compounds. With the majority of pharmaceuticals being petrochemical-based and heavily reliant on overseas manufacturing, this endeavour offers a more sustainable approach to drug synthesis.
The researchers are optimistic about the potential of this project to transform the pharmaceutical industry and address some of the most pressing challenges facing society today. By
38
scottishpharmacist.com
pearheaded by scientists from Impact Solutions, biotechnology researchers from the University of Edinburgh,
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
